B-RAF mutations in tumors from melanoma-breast cancer families [1]

International Journal of Cancer

Volumn 113, Issue 2, 2005, Pages 336-337

  Gast, Andreas ^a   Försti, Asta ^a,b   Söderberg, Magnus ^b   Hemminki, Kari ^a,b   Kumar, Rajiv ^a,b  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b KAROLINSKA INSTITUTE   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

MITOGEN ACTIVATED PROTEIN KINASE; RAF PROTEIN;

BREAST CANCER; CANCER SCREENING; DNA SEQUENCE; FAMILIAL CANCER; GENE MUTATION; GENETIC SUSCEPTIBILITY; HUMAN; LETTER; PRIORITY JOURNAL; SWEDEN;

BREAST NEOPLASMS; DNA MUTATIONAL ANALYSIS; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENETIC SCREENING; HUMANS; MALE; MELANOMA; PEDIGREE; PROTO-ONCOGENE PROTEINS B-RAF; SKIN NEOPLASMS; SWEDEN;

EID: 10344259098     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/ijc.20560     Document Type: Letter

References (15)

1. Hemminki K, Vaittinen P. Interaction of breast cancer and melanoma genotypes. Lancet 1997;350:931-2.
2. Plna K, Hemminki K. Re: high frequency of multiple melanomas and breast and pancreas carcinomas in CDKN2A mutation-positive melanoma families. J Natl Cancer Inst 2001;93:323-5.
3. Borg A, Sandberg T, Nilsson K, Johannsson O, Klinker M, Masback A, Westerdahl J, Olsson H, Ingvar C. High frequency of multiple melanomas and breast and pancreas carcinomas in CDKN2A mutation-positive melanoma families. J Natl Cancer Inst 2000;92:1260-6.
4. Evans HS, Lewis CM, Robinson D, Bell CM, Moller H, Hodgson SV. Cancer risks in women with 2 breast or ovarian cancers: clues to genetic cancer susceptibility. Int J Cancer 2001;94:758-9.
5. Debniak T, Gorski B, Cybulski C, Jakubowska A, Kurzawski G, Kladny J, Zaluga E, Fiedorowicz J, Debniak B, Lubinski J. Increased risk of breast cancer in relatives of malignant melanoma patients from families with strong cancer familial aggregation. Eur J Cancer Prev 2003;12:241-5.
6. Debniak T, Gorski B, Scott RJ, Cybulski C, Medrek K, Zowocka E, Kurzawski G, Debniak B, Kadny J, Bielecka-Grzela S, Maleszka R, Lubinski J. Germline mutation and large deletion analysis of the CDKN2A and ARF genes in families with multiple melanoma or an aggregation of malignant melanoma and breast cancer. Int J Cancer 2004;110:558-62.
7. Eskandarpour M, Hashemi J, Kanter L, Ringborg U., Platz A, Hansson J. Frequency of UV-inducible NRAS mutations in melanomas of patients with germline CDKN2A mutations. J Natl Cancer Inst 2003;95:790-8.
8. Kumar R, Angelini S, Hemminki K. Activating BRAF and N-Ras mutations in sporadic primary melanomas: an inverse association with allelic loss on chromosome 9. Oncogene 2003;22:9217-24.
9. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, Teague J, Woffendin H, Garnett MJ, Bottomley W, Davis N, Dicks E, et al. Mutations of the BRAF gene in human cancer. Nature 2002;417:949-54.
10. Kumar R, Angelini S, Czene K, Sauroja I, Hahka-Kemppinen M, Pyrhonen S, Hemminki K. BRAF mutations in metastatic melanoma: a possible association with clinical outcome. Clin Cancer Res 2003;9:3362-8.
11. Kumar R, Angelini S, Snellman E, Hemminki K. BRAF mutations are common somatic events in melanocytic nevi. J Invest Dermatol 2004;122:342-8.
12. Laud K, Kannengiesser C, Avril M-F, Chompret A, Stoppa-Lyonnet D, Desjardins L, Eychene A, Lenoir GM, Bressac-de Paillerets B, Demenais F, French Hereditary Melanoma Study Group. BRAF as a melanoma susceptibility candidate gene? Cancer Res 2003;63:3061-5.
13. Smalley KS. A pivotal role for ERK in the oncogenic behaviour of malignant melanoma? Int J Cancer 2003;104:527-32.
14. Halaban R. The regulation of normal melanocyte proliferation. Pigment Cell Res 2000;13:4-14.
15. Busca R, Abbe P, Mantoux F, Aberdam E, Peyssonnaux C, Eychene A, Ortonne JP, Ballotti R. Ras mediates the cAMP-dependent activation of extracellular signal-regulated kinases (ERKs) in melanocytes. EMBO J 2000;19:2900-10.